Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMITIL and Radiotherapy in Advanced Cancer
NCT03823989Phase 1Completed
- Sponsor
- LipoMedix
- Start
- Jan 2019
- Primary completion
- Oct 2021
- Modality
- Lipid-based Nanoparticles, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Mitomycin-c lipidic prodrug in solid tumor (3 arms), sponsored by LipoMedix. Primary endpoints: Dose Limiting Toxicity at 6 weeks, Treatment-Emergent Adverse Events at 6 weeks and 1 more. Started Jan 2019; status: completed.
02
Drugs
Mitomycin-c lipidic prodrug
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03823989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823989.